ClinicalTrials.gg
Drug

Lenacapavir clinical trials

Also written GS-6207, Yeztugo® and Sunlenca®.

studies test it
23
open now
9
in phase 3
9
first study started
2018

How each study uses lenacapavir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lenacapavir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Dec 2022 · SUNLENCA · NDA 215973 (FDA, Drugs@FDA)
European Union
17 Aug 2022 · Sunlenca · EMEA/H/C/005638 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lenacapavir
7
Lenacapavir Injection
7
Lenacapavir Tablet
7
LEN
5
Oral Lenacapavir
4

Brand

Yeztugo®
5
Sunlenca®
2

Development codes

GS-6207
13

In one entry with another drug

Given together, or one or the other

Bictegravir/Lenacapavir (BIC/LEN) FDC
2

Studies by the year they started

22 studies that test it; most in 2026 (7); 1 more planned to start later

Studies that test lenacapavir, by start year
YearStudies
20181
20192
20214
20221
20232
20243
20252
20267

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
11
Phase 3
9
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 19 · Other 4

Gilead Sciences (19) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Duke University (1) · Oswaldo Cruz Foundation (1)

Often tested with

Tested in the same studies.

Bictegravir (7) · Tenofovir alafenamide (5) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (5) · Emtricitabine (4) · Teropavimab (2) · Zinlirvimab (2) · GS-3242 (2) · Emtricitabine tenofovir alafenamide (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test lenacapavir.

Studies

Open first, then newest update. How each study uses lenacapavir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 23

See all 23 studies that test lenacapavir →

Given beside what is tested · 5 — lenacapavir is usual care or a partner of the new treatment

Codes

What other systems call lenacapavir · ClinicalTrials.gg INT002095

  • MeSH (NLM) C000730993lenacapavirConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) A9A0O6FB4HLENACAPAVIRConfirmed FDA, NLM, Wikidata
  • Wikidata Q105981469lenacapavirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174616LenacapavirOne source FDA
  • DrugBank DB15673One source Wikidata

Also registered as lenacapavir sodium (UNII BDT58WJ9WE).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.